<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111039</article-id><article-id pub-id-type="publisher-id">ACM-39999</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_48569797.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>åŒ»è¯å«ç”Ÿ</subject></subj-group></article-categories><title-group><article-title>
 
 
  å„¿ç«¥é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœç»¼åˆå¾æ‚£å„¿è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³çš„ç ”ç©¶
  Serum IL-35 and IL-37 Levels in Pediatrics with Obstructive Sleep Apnea Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>æ</surname><given-names>æ ‹æ‰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>ç¨‹</surname><given-names>æ¶µè“‰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>é­</surname><given-names>æ°¸è‰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>æ·±åœ³å¸‚é¾™å²—è€³é¼»å’½å–‰åŒ»é™¢ï¼Œæ·±åœ³è€³é¼»å’½å–‰ç ”ç©¶æ‰€ï¼Œå¹¿ä¸œ æ·±åœ³</addr-line></aff><aff id="aff3"><addr-line>æ·±åœ³å¸‚äººæ°‘åŒ»é™¢å‘¼å¸ç–¾ç—…ç ”ç©¶æ‰€ï¼›å—æ–¹ç§‘æŠ€å¤§å­¦ç¬¬ä¸€é™„å±åŒ»é™¢ï¼Œæš¨å—å¤§å­¦ç¬¬äºŒä¸´åºŠåŒ»å­¦é™¢ï¼Œå¹¿ä¸œ æ·±åœ³</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>268</fpage><lpage>274</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    ç›®çš„ï¼šæ¢è®¨å„¿ç«¥OSASæ‚£è€…è¡€æ¸…çš„IL-35ã€IL-37çš„æ°´å¹³ã€‚æ–¹æ³•ï¼š46ä¾‹æ–°è¯Šæ–­çš„OSASæ‚£è€…å’Œ35ä¾‹éå‘¼å¸æš‚åœå¯¹ç…§è€…è¢«çº³å…¥æœ¬ç ”ç©¶ã€‚äººå£å­¦èµ„æ–™ï¼Œæ—¢å¾€ç¥ç»è‚Œè‚‰ç—…ã€é—ä¼ ä»£è°¢ç—…åŠè¯ç‰©å²ï¼Œä¹ æƒ¯é€šè¿‡æ ‡å‡†åŒ–é—®å·è·å¾—ã€‚æ‰€æœ‰æ‚£è€…å‡æ¥å—å¤šå¯¼ç¡çœ å›¾è¯„ä¼°ã€‚OSASç»„å¹³å‡å¹´é¾„6.8 &#177; 3.3(5~9.5)å²ã€‚OSASç»„ä¸­ä½å‘¼å¸æš‚åœä½é€šæ°”æŒ‡æ•°ä¸º12.5 (6.5~21)ï¼Œä¸­ä½ä½“é‡æŒ‡æ•°ä¸º20.5 (18~24.2)ã€‚é‡‡ç”¨ELISAæ³•æ£€æµ‹è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³ã€‚ç»“æœï¼šOSASæ‚£è€…è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³å‡æ˜æ˜¾ä½äºå¥åº·äººã€‚éšç€OSASç–¾ç—…çš„ç¨‹åº¦åŠ é‡ï¼Œè¡€æ¸…IL-35ã€IL-37æ°´å¹³è¿›ä¸€æ­¥é™ä½ï¼Œå…¶å·®å¼‚ä¹Ÿå…·æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ã€‚ç»“è®ºï¼šæœ¬ç ”ç©¶æç¤ºè¡€æ¸…IL-35å’ŒIL-37å¯èƒ½æ˜¯OSASçš„æ–°çš„ç”Ÿç‰©æ ‡å¿—ç‰©ï¼Œæç¤ºè°ƒèŠ‚è¿™ä¸¤ç§ç»†èƒå› å­çš„è¡¨è¾¾å¯èƒ½ä¸ºOSASçš„æ²»ç–—æä¾›æ–°çš„å¯èƒ½é¶ç‚¹ã€‚
    Objective: The aim of the present study was to investigate the serum level of IL-35. IL-37 in patients with OSAS. Methods: 46 newly diagnosed pediatrics OSAS patients and 35 non-apneic controls were enrolled in this study. Demographic data, previous history of diseases including metabolic diseases and drugs, and habits were obtained by a standardized questionnaire. All patients underwent polysomnographic evaluation. The mean age was 6.8 &#177; 3.3 (5~9.5) years in the OSAS group. Median apnea-hypopnea index was 12.5 (6.5~21) and median body mass index was 20.5 (18~24.2) in the OSAS group. Cytokine levels in serum were determined using ELISA. Results: The results showed that serums IL-35 and IL-37 levels were significantly decreased in OSAS patients compared with healthy subjects. The cytokine levels correlated inversely with OSAS severity. Conclusion: The study showed that serums IL-35 and IL-37 might be potentially novel biomarkers for OSAS, suggesting that regulating the expression of the two cytokines may provide a new possible target for the treatment of OSAS. 
  
 
</p></abstract><kwd-group><kwd>ç™½ç»†èƒä»‹ç´ -35ï¼Œç™½ç»†èƒä»‹ç´ -37ï¼Œé˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœç»¼åˆå¾ï¼Œç‚ç—‡, Interleukin-35</kwd><kwd> Interleukin-37</kwd><kwd> Obstructive Sleep Apnea Syndrome</kwd><kwd> In?ammation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>æ‘˜è¦</title><p>ç›®çš„ï¼šæ¢è®¨å„¿ç«¥OSASæ‚£è€…è¡€æ¸…çš„IL-35ã€IL-37çš„æ°´å¹³ã€‚æ–¹æ³•ï¼š46ä¾‹æ–°è¯Šæ–­çš„OSASæ‚£è€…å’Œ35ä¾‹éå‘¼å¸æš‚åœå¯¹ç…§è€…è¢«çº³å…¥æœ¬ç ”ç©¶ã€‚äººå£å­¦èµ„æ–™ï¼Œæ—¢å¾€ç¥ç»è‚Œè‚‰ç—…ã€é—ä¼ ä»£è°¢ç—…åŠè¯ç‰©å²ï¼Œä¹ æƒ¯é€šè¿‡æ ‡å‡†åŒ–é—®å·è·å¾—ã€‚æ‰€æœ‰æ‚£è€…å‡æ¥å—å¤šå¯¼ç¡çœ å›¾è¯„ä¼°ã€‚OSASç»„å¹³å‡å¹´é¾„6.8 &#177; 3.3(5~9.5)å²ã€‚OSASç»„ä¸­ä½å‘¼å¸æš‚åœä½é€šæ°”æŒ‡æ•°ä¸º12.5 (6.5~21)ï¼Œä¸­ä½ä½“é‡æŒ‡æ•°ä¸º20.5 (18~24.2)ã€‚é‡‡ç”¨ELISAæ³•æ£€æµ‹è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³ã€‚ç»“æœï¼šOSASæ‚£è€…è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³å‡æ˜æ˜¾ä½äºå¥åº·äººã€‚éšç€OSASç–¾ç—…çš„ç¨‹åº¦åŠ é‡ï¼Œè¡€æ¸…IL-35ã€IL-37æ°´å¹³è¿›ä¸€æ­¥é™ä½ï¼Œå…¶å·®å¼‚ä¹Ÿå…·æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ã€‚ç»“è®ºï¼šæœ¬ç ”ç©¶æç¤ºè¡€æ¸…IL-35å’ŒIL-37å¯èƒ½æ˜¯OSASçš„æ–°çš„ç”Ÿç‰©æ ‡å¿—ç‰©ï¼Œæç¤ºè°ƒèŠ‚è¿™ä¸¤ç§ç»†èƒå› å­çš„è¡¨è¾¾å¯èƒ½ä¸ºOSASçš„æ²»ç–—æä¾›æ–°çš„å¯èƒ½é¶ç‚¹ã€‚</p></sec><sec id="s2"><title>å…³é”®è¯</title><p>ç™½ç»†èƒä»‹ç´ -35ï¼Œç™½ç»†èƒä»‹ç´ -37ï¼Œé˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœç»¼åˆå¾ï¼Œç‚ç—‡</p></sec><sec id="s3"><title>Serum IL-35 and IL-37 Levels in Pediatrics with Obstructive Sleep Apnea Syndrome<sup> </sup></title><p>Dongcai Li<sup>1</sup>, Hanrong Cheng<sup>2*</sup>, Yongli Wei<sup>2</sup></p><p><sup>1</sup>Institute of Shenzhen ENT, Longgang ENT Hospital, Shenzhen Guangdong</p><p><sup>2</sup>Institute of Respiratory Diseases, Shenzhen Peopleâ€™s Hospital; The Second Clinical Medical College of Jinan University, 1st Affiliated Hospital of Southern University of Science and Technology, Shenzhen Guangdong</p><p><img src="//html.hanspub.org/file/39-1571859x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/39-1571859x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The aim of the present study was to investigate the serum level of IL-35. IL-37 in patients with OSAS. Methods: 46 newly diagnosed pediatrics OSAS patients and 35 non-apneic controls were enrolled in this study. Demographic data, previous history of diseases including metabolic diseases and drugs, and habits were obtained by a standardized questionnaire. All patients underwent polysomnographic evaluation. The mean age was 6.8 &#177; 3.3 (5~9.5) years in the OSAS group. Median apnea-hypopnea index was 12.5 (6.5~21) and median body mass index was 20.5 (18~24.2) in the OSAS group. Cytokine levels in serum were determined using ELISA. Results: The results showed that serums IL-35 and IL-37 levels were significantly decreased in OSAS patients compared with healthy subjects. The cytokine levels correlated inversely with OSAS severity. Conclusion: The study showed that serums IL-35 and IL-37 might be potentially novel biomarkers for OSAS, suggesting that regulating the expression of the two cytokines may provide a new possible target for the treatment of OSAS.</p><p>Keywords:Interleukin-35, Interleukin-37, Obstructive Sleep Apnea Syndrome, Inï¬‚ammation</p><disp-formula id="hanspub.39999-formula28"><graphic xlink:href="//html.hanspub.org/file/39-1571859x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/39-1571859x8_hanspub.png" /> <img src="//html.hanspub.org/file/39-1571859x9_hanspub.png" /></p></sec><sec id="s5"><title>1. å¼•è¨€</title><p>é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœç»¼åˆå¾(Obstructive sleep apnea syndrome, OSAS)æ˜¯ä¸€ç§å¹¿æ³›çš„ç–¾ç—…ï¼Œå…¶ç‰¹å¾æ˜¯ç¡çœ æ—¶åå¤å‡ºç°å®Œå…¨æˆ–éƒ¨åˆ†ä¸Šæ°”é“é˜»å¡ï¼Œä¼´éšåŠ¨è„‰è¡€æ°§é¥±å’Œåº¦ä¸‹é™å’Œç¡çœ å”¤é†’ï¼Œå¯¼è‡´ç™½å¤©è¿‡åº¦å—œç¡å¹¶å¼•èµ·å…¶ä»–ç™½å¤©ç—‡çŠ¶ [<xref ref-type="bibr" rid="hanspub.39999-ref1">1</xref>]ã€‚åœ¨å„¿ç«¥ï¼ŒOSAHSçš„ç—…å› æ˜¯è…ºæ ·ä½“è‚¥å¤§ï¼Œæ‰æ¡ƒä½“è‚¥å¤§ç­‰æ–¹é¢çš„å› ç´ ï¼Œå¹¶å¯¼è‡´ç‚ç—‡å’Œé—´æ­‡æ€§ä½æ°§æ‰€è‡´ [<xref ref-type="bibr" rid="hanspub.39999-ref2">2</xref>]ã€‚ç™½ç»†èƒä»‹ç´ (IL-35)å’ŒIL-37æ˜¯æ–°è¿‘å‘ç°çš„å…ç–«æŠ‘åˆ¶ç»†èƒå› å­ã€‚IL-35å±äºIL-12å®¶æ—ï¼Œå«æœ‰IL-12ï¼ŒIL-23å’ŒIL-27ã€‚å®ƒç”±EBç—…æ¯’è¯±å¯¼åŸºå› 3 (Ebi3)å’Œp35 (IL-12a)ä¸¤ä¸ªäºšåŸºç»„æˆ [<xref ref-type="bibr" rid="hanspub.39999-ref3">3</xref>]ã€‚åœ¨å°é¼ ä¸­ï¼ŒIL-35ç”±Foxp3+CD4+CD25+è°ƒèŠ‚æ€§Tç»†èƒ(Tregs)åˆ†æ³Œï¼Œåœ¨å®éªŒæ€§è‡ªèº«å…ç–«æ€§è„‘è„Šé«“ç‚(EAE)ä¸­ï¼ŒIL-35å’ŒCD138+æµ†ç»†èƒè¯±å¯¼çš„è°ƒèŠ‚æ€§Tç»†èƒç¾¤ [<xref ref-type="bibr" rid="hanspub.39999-ref4">4</xref>] åˆ†æ³Œã€‚åˆ©ç”¨å®éªŒæ•°æ®åº“æŒ–æ˜å’Œç»Ÿè®¡åˆ†ææ–¹æ³•ï¼ŒLiç­‰äººæŠ¥é“IL-35åœ¨äººä½“ç»„ç»‡ä¸­ä¸æ˜¯ç»„æˆå‹è¡¨è¾¾ï¼Œä½†åœ¨ç‚ç—‡åˆºæ¿€ä¸‹æ˜¯å¯è¯±å¯¼çš„ [<xref ref-type="bibr" rid="hanspub.39999-ref5">5</xref>]ã€‚IL-37åˆç§°IL-1F7ï¼Œæ˜¯IL-1å®¶æ—çš„ä¸€ä¸ªæ–°æˆå‘˜ï¼Œå…·æœ‰ç±»ä¼¼æ¡¶çŠ¶ç»“æ„çš„å…±åŒç‰¹å¾ã€‚IL-37Bæ˜¯äº”ç§å˜å¼‚ä½“ä¸­æœ€å¤§çš„åŒå·¥å‹ï¼Œåœ¨äººç±»å¤šç§æ­£å¸¸ç»„ç»‡å’Œè‚¿ç˜¤ä¸­è¡¨è¾¾ [<xref ref-type="bibr" rid="hanspub.39999-ref6">6</xref>]ã€‚æœ€æ—©åœ¨éª¨é«“ä¸­å‘ç°ï¼Œä¸­æ€§ç²’ç»†èƒæ˜¯å…¶åˆæˆçš„ä¸»è¦åœºæ‰€ã€‚ä¸»è¦è¡¨è¾¾äºè¡€ç»†èƒï¼Œå‘¼å¸é“ï¼Œèƒƒè‚ é“ï¼Œä»¥åŠçš®è‚¤è§’è´¨å½¢æˆç»†èƒ [<xref ref-type="bibr" rid="hanspub.39999-ref7">7</xref>]ã€‚åœ¨æœ¬ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬æ—¨åœ¨è°ƒæŸ¥è¡€æµ†IL-35å’ŒIL-37æ°´å¹³ä¸OSASä¸¥é‡ç¨‹åº¦ä¹‹é—´çš„å…³ç³»ï¼Œè¯¥ä¸¥é‡ç¨‹åº¦ç”±å‘¼å¸æš‚åœä½é€šæ°”æŒ‡æ•°(AHI)ç¡®å®šã€‚</p></sec><sec id="s6"><title>2. èµ„æ–™ä¸æ–¹æ³•</title><sec id="s6_1"><title>2.1. æ‚£è€…é€‰æ‹©</title><p>æˆ‘ä»¬å‰ç»æ€§è¯„ä¼°äº†2019å¹´2æœˆè‡³2020å¹´2æœˆé—´åœ¨æ·±åœ³å¸‚é¾™å²—è€³é¼»å–‰åŒ»é™¢ç¡çœ åŒ»å­¦ä¸­å¿ƒå°±è¯Šçš„æ‚£è€…ã€‚è¿™é¡¹ç ”ç©¶å¾—åˆ°äº†æ·±åœ³å¸‚é¾™å²—è€³é¼»å–‰åŒ»é™¢ä¼¦ç†å§”å‘˜ä¼šçš„æ‰¹å‡†ï¼Œæ‰€æœ‰æ‚£è€…éƒ½ç­¾ç½²ä¹¦é¢çŸ¥æƒ…åŒæ„ä¹¦ã€‚46ä¾‹æ–°è¯Šæ–­çš„OSASæ‚£å„¿å’Œ35ä¾‹å¹´é¾„åŒ¹é…çš„éå‘¼å¸æš‚åœå¯¹ç…§è€…è¢«çº³å…¥æœ¬ç ”ç©¶ã€‚æ’é™¤ä¸­æ¢æ€§ç¡çœ å‘¼å¸æš‚åœã€ä¸Šæ°”é“é˜»åŠ›ç»¼åˆå¾ã€è‚ºéƒ¨ç–¾ç—…ã€ç”²çŠ¶è…ºåŠŸèƒ½ä½ä¸‹åŠç³–å°¿ç—…ç­‰å†…åˆ†æ³Œç–¾ç—…ã€é—ä¼ ä»£è°¢ç—…åŠç¥ç»è‚Œè‚‰ç—…æ‚£è€…ã€‚è®°å½•å¹´é¾„ï¼Œæ€§åˆ«ï¼Œä½“é‡æŒ‡æ•°(BMI)ç­‰äººå£ç»Ÿè®¡å­¦èµ„æ–™ã€‚ç”¨Epworthå—œç¡é‡è¡¨å¯¹æ¯ä½æ‚£è€…è¿›è¡Œå—œç¡è¯„å®šã€‚</p></sec><sec id="s6_2"><title>2.2. å¤šå¯¼ç¡çœ å›¾è¯„ä¼°</title><p>é€šè¿‡è®¡ç®—æœºåŒ–ç³»ç»Ÿ(åº·è¿ªCompumedics Grael)å¯¹æ‰€æœ‰æ‚£è€…è¿›è¡Œå…¨å¤œè¯Šæ–­æ€§å¤šå¯¼ç¡çœ æè®°æœ¯(PSG)ï¼Œè®°å½•è„‘ç”µå›¾ï¼Œçœ¼ç”µå›¾ï¼Œé¢ä¸‹è‚Œç”µå›¾(EMG)ï¼ŒåŒä¾§èƒ«éª¨å‰è‚Œç”µå›¾ï¼Œå¿ƒç”µå›¾ï¼Œé€šè¿‡ç”µæ„Ÿå®¹ç§¯æè®°æ³•è¿›è¡Œçš„èƒ¸å£å’Œè…¹å£è¿åŠ¨ï¼Œé€šè¿‡é¼»å‹ä¼ æ„Ÿå™¨æµ‹é‡ï¼Œå¹¶è¾…ä»¥å£è…”çƒ­æ•ç”µé˜»å™¨ï¼Œè„‰å†²è¡€æ°§è®¡ï¼Œæ ¹æ®ç¾å›½ç¡çœ åŒ»å­¦å­¦ä¼šçš„æ ‡å‡†ï¼Œå¤šå¯¼ç¡çœ æè®°è®°å½•åœ¨30ç§’å†…å¯¹ç¡çœ ï¼Œå‘¼å¸å’Œæ°§åˆè¿›è¡Œè¯„åˆ†ã€‚å„¿ç«¥ç¡çœ å‘¼å¸æš‚åœ [<xref ref-type="bibr" rid="hanspub.39999-ref8">8</xref>] æ˜¯ä¸€ç§å¸¸è§çš„ç¡çœ å‘¼å¸éšœç¢æ€§ç–¾ç—…ï¼Œæ˜¯æŒ‡ç¡çœ è¿‡ç¨‹ä¸­é¢‘ç¹å‘ç”Ÿéƒ¨åˆ†æˆ–å…¨éƒ¨ä¸Šæ°”é“é˜»å¡ï¼Œå£ã€é¼»æ°”æµåœæ­¢æŒç»­æ—¶é—´è‡³å°‘ä¸º2ä¸ªå‘¼å¸å‘¨æœŸä»¥ä¸Šï¼Œåˆ†ä¸ºä¸­æ¢æ€§(central sleep apnea, CSA)ã€é˜»å¡æ€§(obstructive sleep apnea, OSA)å’Œæ··åˆæ€§ä¸‰ç±»ï¼Œå…¶ä¸­æœ€å¸¸è§çš„æ˜¯é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœä½é€šæ°”ç»¼åˆå¾(obstructive sleep apnea hypopnea syndrome, OSAHS)ï¼Œå„¿ç«¥OSAHS æ˜¯æŒ‡å£é¼»æ°”æµåœæ­¢æˆ–æ°”æµå‡å°‘30%ä»¥ä¸Šï¼Œä½†å­˜åœ¨å‘¼å¸è¿åŠ¨ï¼Œå¼•èµ·å‘¼å¸æš‚åœå’Œé€šæ°”ä¸è¶³æŒç»­æ—¶é—´è‡³å°‘ä¸º2ä¸ªå‘¼å¸å‘¨æœŸä»¥ä¸Šï¼Œä¼´æœ‰æ‰“é¼¾ã€ç¡çœ ç»“æ„ç´Šä¹±ï¼Œä½é€šæ°”äº‹ä»¶ä¼´æœ‰è¡€æ°§é¥±å’Œåº¦ä¸‹é™3%ä»¥ä¸Šï¼Œè·Ÿæ®AASMæ ‡å‡†ï¼ŒAHI â‰¥ 1å³è¯Šæ–­ä¸ºå„¿ç«¥OSAã€‚æ ¹æ®OSASçš„ä¸¥é‡ç¨‹åº¦åˆ†ä¸ºAHI = 1~5çš„è½»åº¦OSASç»„ï¼ŒAHI = 5~10çš„ä¸­åº¦OSASç»„å’ŒAHI â‰¥ 10çš„é‡åº¦OSASç»„ [<xref ref-type="bibr" rid="hanspub.39999-ref9">9</xref>]ã€‚</p></sec><sec id="s6_3"><title>2.3. IL-35å’ŒIL-37æµ‹å®š</title><p>åœ¨è¿›è¡Œå¤šå¯¼ç¡çœ æè®°æœ¯åçš„ç¬¬äºŒå¤©æ—©æ™¨æŠ½å–é™è„‰è¡€æ ·æœ¬ï¼Œåœ¨å®¤æ¸©ä¸‹ä»¥1500 &#215; gç¦»å¿ƒ20åˆ†é’Ÿï¼Œæ”¶é›†è¡€æ¸…å¹¶åœ¨âˆ’80â„ƒä¿å­˜ç›´ï¼Œç›´åˆ°æµ‹å®šç»“æœã€‚ç”¨å¸‚å”®é…¶è”å…ç–«å¸é™„è¯•éªŒ(ELISA)è¯•å‰‚ç›’ï¼šIL-37 (Ab 213798)ï¼ŒIL-35 (70-EK135-96)æµ‹å®šè¡€æ¸…IL-35å’ŒIL-37ã€‚æ‰€æœ‰ç»†èƒå› å­æµ‹å®šå‡ä¸€å¼ä¸¤ä»½ï¼Œå¹¶æŒ‰ç…§åˆ¶é€ å•†çš„æ–¹æ¡ˆè¿›è¡Œã€‚</p></sec><sec id="s6_4"><title>2.4. ç»Ÿè®¡åˆ†æ</title><p>ç”¨GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA)å’ŒSPSS19.0 (SPSS Inc., Chicago, IL, USA)è¿›è¡Œç»Ÿè®¡è¯„ä»·ã€‚æ•°æ®ä»¥å‡å€¼&#177;æ ‡å‡†è¯¯å·®(SEM)è¡¨ç¤ºã€‚ç”¨æ–¹å·®åˆ†æè¯„ä»·è¡€æ¸…ä¸­ç»†èƒå› å­è¡¨è¾¾çš„å·®å¼‚ã€‚åœ¨æ‰€æœ‰è¯•éªŒä¸­ï¼ŒP &lt; 0.05è¢«è®¤ä¸ºæ˜¯æ˜¾è‘—çš„ã€‚</p></sec></sec><sec id="s7"><title>3. ç»“æœ</title><p>æœ¬ç ”ç©¶çº³å…¥äº†46ä¾‹OSASæ‚£è€…å’Œ35åå¯¹ç…§å—è¯•è€…ã€‚è¡¨1åˆ—å‡ºäº†è¿™ä¸¤ä¸ªç ”ç©¶ç»„çš„åŸºçº¿ç‰¹å¾å’Œä¸´åºŠå‘ç°ï¼šOSASæ‚£è€…ä¸å¯¹ç…§ä¹‹é—´çš„å¹´é¾„å’Œæ€§åˆ«æ— å·®å¼‚ã€‚OSASç»„ä¸º6.8 &#177; 3.3 (5~9.5)å²ï¼Œå¯¹ç…§ç»„ä¸º6.6 &#177; 3.6 (5.5~9.5)å²ã€‚81ä¾‹æ‚£è€…ä¸­æœ‰46ä¾‹(ç”·26ä¾‹ï¼Œå¥³æ€§20ä¾‹)è¢«åˆ†ç±»ä¸ºOSASï¼Œ35ä¾‹(20ä¾‹ç”·æ€§ï¼Œ15ä¾‹å¥³æ€§)ä½œä¸ºå¯¹ç…§ç»„ã€‚å¯¹ç…§ç»„ä¸ºå¥åº·å—è¯•è€…ï¼Œæ— ç¡çœ å‘¼å¸æš‚åœã€‚OSASç»„ä¸­ï¼ŒAHIä¸­ä½æ•°ä¸º12.5 (6.5~21)ï¼ŒBMIä¸­ä½æ•°ä¸º20.5 (18~24.2)ã€‚æ ¹æ®AHIå°†æ‚£è€…åˆ†ä¸ºè½»åº¦OSASç»„(n = 10, 21.7%)ï¼Œä¸­åº¦OSASç»„(n = 20, 43.5%)å’Œé‡åº¦OSASç»„(n = 16, 34.8%)ã€‚</p><p>OSAS æ‚£è€…è¡€æ¸…IL-35ï¼ŒIL-37æ°´å¹³é™ä½ã€‚OSASæ‚£è€…è¡€æ¸…IL-35å’ŒIL-37æµ“åº¦ä¸å¥åº·å¯¹ç…§(HC)ç›¸æ¯”ï¼Œå…¶å·®å¼‚å…·æœ‰ç»Ÿè®¡å­¦æ„ä¹‰(è¡¨2)ã€‚è½»åº¦OSASä¸ä¸­åº¦OSASï¼Œè½»åº¦OSASä¸é‡åº¦OSASï¼Œä¸­åº¦OSASä¸é‡åº¦OSASä¹‹é—´ï¼Œéšç€OSASç–¾ç—…çš„ç¨‹åº¦åŠ é‡ï¼Œè¡€æ¸…IL-35ï¼ŒIL-37æ°´å¹³è¿›ä¸€æ­¥é™ä½ï¼Œå…¶å·®å¼‚ä¹Ÿå…·æœ‰ç»Ÿè®¡å­¦æ„ä¹‰(P &lt; 0.05) (è¡¨2)ã€‚</p></sec><sec id="s8"><title>4. è®¨è®º</title><p>é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœç»¼åˆå¾(obstructive sleep apnea syndrome, OSAS)æ˜¯æŒ‡ç¡çœ æ—¶å‡ºç°ä¸Šæ°”é“å’½è…”æ°´å¹³åå¤çš„å¡Œé™·ä¸ºä¸»è¦ç‰¹å¾ï¼Œä¸»è¦è¡¨ç°ä¸ºç¡çœ æ—¶æ‰“é¼¾å¹¶ä¼´æœ‰å‘¼å¸æš‚åœï¼Œå¤œé—´åå¤å‘ç”Ÿä½æ°§è¡€ç—‡ã€é«˜ç¢³é…¸è¡€</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of OSAS and control grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >æ‚£è€…åŸºæœ¬ä¿¡æ¯</th><th align="center" valign="middle" >æ­£å¸¸å¯¹ç…§ç»„</th><th align="center" valign="middle" >OSASç»„</th><th align="center" valign="middle" >P å€¼</th></tr></thead><tr><td align="center" valign="middle" >ä¾‹æ•°</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >æ€§åˆ«(F/M)</td><td align="center" valign="middle" >15/20</td><td align="center" valign="middle" >20/26</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >å¹´é¾„(å²)</td><td align="center" valign="middle" >6.6 &#177; 3.6 (5.5~9.5)</td><td align="center" valign="middle" >6.8 &#177; 3.3 (5~9.5)</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >AHIç»„åˆ«ä¾‹æ•°</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >0~1</td><td align="center" valign="middle" >35 (100%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1~5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10 (21.7%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >5~10</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >20 (43.5%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&gt;10</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >16 (34.8%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;24.9</td><td align="center" valign="middle" >19.6 (17~23.2)</td><td align="center" valign="middle" >20.5 (18~24.2)</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >å…±æ‚£ç—…</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >ç³–å°¿ç—…åŠç”²çŠ¶è…ºç–¾ç—…</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >ç¥ç»è‚Œè‚‰ç—…</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >ns</td></tr><tr><td align="center" valign="middle" >é—ä¼ ä»£è°¢ç—…</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >ns</td></tr></tbody></table></table-wrap><p>è¡¨1. OSASä¸å¯¹ç…§ç»„çš„æ¯”è¾ƒ</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Serum levels of IL-35 and IL-37 in OSAS and control group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >æ­£å¸¸å¯¹ç…§ç»„</th><th align="center" valign="middle" >è½»åº¦OSAS</th><th align="center" valign="middle" >ä¸­åº¦OSAS</th><th align="center" valign="middle" >é‡åº¦OSAS</th></tr></thead><tr><td align="center" valign="middle" >IL-35 (ng/mL)</td><td align="center" valign="middle" >1866.96 &#177; 209.43****</td><td align="center" valign="middle" >956.17 &#177; 219.38***</td><td align="center" valign="middle" >465.26 &#177; 160.36**</td><td align="center" valign="middle" >216.33&#177; 36.26*</td></tr><tr><td align="center" valign="middle" >IL-37 (ng/mL)</td><td align="center" valign="middle" >2189.68 &#177; 261.24^^^^</td><td align="center" valign="middle" >1105.67 &#177; 232.82^^^</td><td align="center" valign="middle" >502.66 &#177; 138.56^^</td><td align="center" valign="middle" >186.89 &#177; 36.50^</td></tr></tbody></table></table-wrap><p>è¡¨2. OSASä¸å¯¹ç…§ç»„è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³</p><p>å„ç»„ä¹‹é—´IL-35æ°´å¹³æ¯”è¾ƒï¼ŒP &lt; 0.05ï¼›å„ç»„ä¹‹é—´IL-37æ°´å¹³æ¯”è¾ƒï¼ŒP &lt; 0.05ã€‚</p><p>ç—‡å’Œç¡çœ ç»“æ„ç´Šä¹±ï¼Œå¯é€ æˆå¤šè„å™¨æŸå®³ [<xref ref-type="bibr" rid="hanspub.39999-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref10">10</xref>]ã€‚ç”±äºå‘¼å¸æš‚åœå¼•èµ·åå¤å‘ä½œçš„å¤œé—´ä½æ°§å’Œé«˜ç¢³é…¸è¡€ç—‡ï¼Œå¯å¯¼è‡´é«˜è¡€å‹ã€å† å¿ƒç—…ã€å¿ƒå¾‹å¤±å¸¸ã€ç³–å°¿ç—…ç­‰ï¼Œè€Œå¿ƒã€è„‘è¡€ç®¡çš„åˆå¹¶ç—‡æœ€ä¸ºå¸¸è§å’Œä¸¥é‡ï¼Œç”šè‡³å‡ºç°å¤œé—´çŒæ­»ã€‚ç›®å‰è‚¥èƒ–çš„å‘ç”Ÿç‡å¢åŠ ï¼Œå› æ­¤ï¼ŒOSASçš„å‘ç”Ÿç‡ä¹Ÿéšä¹‹å‡é«˜ã€‚ä¼—æ‰€å‘¨çŸ¥ï¼Œå¤šå¯¼ç¡çœ å›¾æ˜¯å…¶æ ‡å‡†è¯Šæ–­ï¼Œç„¶è€Œå®ƒå…·æœ‰ä¸€å®šçš„å±€é™æ€§ï¼ŒåŒ…æ‹¬æˆæœ¬ã€æœ‰é™å¯ç”¨æ€§åŠéœ€è¦æ‚£è€…çš„ç§¯æé…åˆï¼Œå› æ­¤ç‚ç—‡å› å­åŠä»£è°¢æŒ‡æ ‡åœ¨è¯„ä¼°OSASå¹¶å‘ç—‡ä¸­èµ·åˆ°äº†é‡è¦çš„ä½œç”¨ [<xref ref-type="bibr" rid="hanspub.39999-ref11">11</xref>]ã€‚æ—©æœŸçš„é¢„æµ‹å› å­ä¸ºä¸´åºŠæä¾›ä¾æ®ï¼Œæ—©å‘ç°ï¼Œæ—©æ²»ç–—ï¼Œç§¯æå¹²é¢„ï¼Œæé«˜æ‚£è€…çš„ç”Ÿæ´»è´¨é‡ï¼Œå‡å°‘å‘ç”Ÿä¸è‰¯äº‹ä»¶å…·æœ‰éå¸¸é‡è¦çš„æ„ä¹‰ã€‚</p><p>OSASåœ¨å„¿ç«¥ä¸­è¡¨ç°ä¸ºè¡Œä¸ºå¼‚å¸¸ï¼Œæ³¨æ„åŠ›éšœç¢ï¼Œç™½å¤©è¿‡åº¦å—œç¡ã€å¤šåŠ¨ï¼Œä¸¥é‡è€…å¯å¼•èµ·è‚ºå¿ƒç—…ï¼Œç”Ÿé•¿å‘è‚²è¿Ÿç¼“ï¼Œå¯¹å„¿ç«¥çš„èº«ä½“å¥åº·ã€æ™ºåŠ›å‘è‚²å’Œç”Ÿé•¿å¸¦æ¥æå¤§å½±å“ï¼Œä¸¥é‡å¨èƒå„¿ç«¥å¥åº·ã€‚OSAHSçš„ç—…å› åŒ…æ‹¬è…ºæ ·ä½“è‚¥å¤§ï¼Œæ‰æ¡ƒä½“è‚¥å¤§ã€é¼»ä¸­éš”åæ›²ã€å°ä¸‹é¢Œã€é¼»ç”²è‚¥å¤§ã€é¼»æ¯è‚‰ç­‰è§£å‰–æ–¹é¢çš„å› ç´ ï¼Œå¼•èµ·ç‚ç—‡å› å­TNF-aã€IL-6ã€IL-10ã€CRPè¿‡åº¦é‡Šæ”¾ç­‰ç›¸å…³ï¼Œä¸»è¦æ˜¯é—´æ­‡æ€§ä½æ°§å¯¼è‡´ [<xref ref-type="bibr" rid="hanspub.39999-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref14">14</xref>]ã€‚</p><p>åˆ°ç›®å‰ä¸ºæ­¢ï¼ŒCååº”è›‹ç™½(CRP)å’Œè‚¿ç˜¤åæ­»å› å­ç­‰ä¸´åºŠæ ‡å¿—ç‰©å·²è¢«æŠ¥é“ä¸OSASæœ‰å…³ [<xref ref-type="bibr" rid="hanspub.39999-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39999-ref16">16</xref>]ã€‚Mehraç­‰äººå·²ç»è¯æ˜OSASæ‚£è€…ä¸å¯¹ç…§ç»„ç›¸æ¯”IL-6æ°´å¹³å‡é«˜ [<xref ref-type="bibr" rid="hanspub.39999-ref17">17</xref>]ã€‚è™½ç„¶æœ‰ä¸€äº›æœ‰è¯´æœåŠ›çš„ç»“æœï¼Œä½†ä»‹ä½“æ°´å¹³çš„å‡é«˜è¢«è®¤ä¸ºæ˜¯OSASæ‚£è€…ç¼ºæ°§å’Œè‚¥èƒ–çš„ç»§å‘æ€§å› ç´ ã€‚Nuralç­‰äººæŠ¥é“äº†æŒç»­æ°”é“æ­£å‹(CPAP)æ²»ç–—åè¡€æ¸…CRPæ°´å¹³æ˜¾è‘—é™ä½ [<xref ref-type="bibr" rid="hanspub.39999-ref18">18</xref>]ã€‚åœ¨æœ€è¿‘çš„ä¸€é¡¹ç ”ç©¶ä¸­ï¼Œä½œè€…å‘ç°åœ¨è°ƒæ•´å¹´é¾„ã€è…°å›´å’Œå¸çƒŸåï¼ŒAHIå’ŒIL-6æ°´å¹³ä¹‹é—´æ²¡æœ‰æ˜æ˜¾çš„ç›¸å…³æ€§ [<xref ref-type="bibr" rid="hanspub.39999-ref19">19</xref>]ã€‚Yokoeåœ¨Alçš„æŠ¥å‘Šä¸­ä¹Ÿæœ‰ç±»ä¼¼çš„å‘ç° [<xref ref-type="bibr" rid="hanspub.39999-ref20">20</xref>]ã€‚é™¤æ­¤ä¹‹å¤–ï¼ŒVgontzasç­‰äºº [<xref ref-type="bibr" rid="hanspub.39999-ref21">21</xref>] å‘ç°OSASæ‚£è€…çš„IL-6å’ŒTNF-aæ°´å¹³é«˜äºå¥åº·å—è¯•è€…ã€‚IL-37è¢«è®¤ä¸ºå…·æœ‰è½¬ä½åˆ°ç»†èƒæ ¸çš„åŠŸèƒ½ï¼Œå¹¶èƒ½åœ¨ç»†èƒå†…å¤–é‡æ–°åˆ†å¸ƒã€‚IL-37å‘ç»†èƒå†…è½¬ç§»å¯èƒ½æ˜¯è¡€æ¸…ä¸­IL-37å«é‡ä¸‹é™çš„åŸå› ã€‚ç ”ç©¶è¡¨æ˜ï¼Œè¡€æ¸…IL-35å’ŒIL-37æ°´å¹³é™ä½å¯èƒ½ä»£è¡¨ä½“å†…æŠ—ç‚æ´»æ€§ä¸è¶³ï¼Œå¹¶æœ‰æœ›ä½œä¸ºç›‘æµ‹OSASç–¾ç—…ä¸¥é‡ç¨‹åº¦çš„æ–°ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚åœ¨æœ¬ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬é¦–æ¬¡è¯å®OSASæ‚£è€…è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³æ˜¾è‘—ä½äºå¥åº·å¯¹ç…§ç»„ï¼Œå¹¶ä¸”éšç€OSASç–¾ç—…çš„ç¨‹åº¦åŠ é‡ï¼Œè¡€æ¸…IL-35ï¼ŒIL-37æ°´å¹³è¿›ä¸€æ­¥é™ä½ï¼Œå…¶å·®å¼‚ä¹Ÿå…·æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ã€‚</p><p>IL-35å’ŒIL-37çš„ä½œç”¨æœºåˆ¶ç›®å‰å°šä¸æ¸…æ¥šã€‚IL-35å‚ä¸ç¥ç»ç³»ç»Ÿã€æ¶ˆåŒ–ç³»ç»Ÿã€éª¨å…³èŠ‚ç³»ç»Ÿå’Œå‘¼å¸ç³»ç»Ÿçš„ç‚ç—‡æ€§ç–¾ç—…ã€‚Zandianç­‰äººè¯æ˜IL-35é€šè¿‡é˜»æ­¢è‡ªèº«ä¾µè¢­æ€§Tç»†èƒçš„å‘å±•è€Œå…·æœ‰æŠ‘åˆ¶è„±é«“é˜çš„ä½œç”¨ [<xref ref-type="bibr" rid="hanspub.39999-ref22">22</xref>]ã€‚Kochetkovaç­‰äººæç¤ºå¤–æºæ€§IL-35å¯æŠ‘åˆ¶CD4+Tç»†èƒï¼ŒTh1å’ŒTh17ç»†èƒçš„æ´»æ€§ï¼ŒæŠ‘åˆ¶èƒ¶åŸè¯±å¯¼æ€§å…³èŠ‚ç‚çš„ç‚ç—‡ [<xref ref-type="bibr" rid="hanspub.39999-ref23">23</xref>]ã€‚åŒæ—¶ï¼Œæç¤ºIL-35å¯ä»¥å¸®åŠ©å‘¼å¸ç³»ç»Ÿä»ç‚ç—‡ä¸­æ¢å¤ [<xref ref-type="bibr" rid="hanspub.39999-ref24">24</xref>]ã€‚Wirtzç­‰äººæœ€è¿‘è¯å®IL-35èƒ½æ˜¾è‘—æŠ‘åˆ¶Th1å’ŒTh17ç»†èƒçš„å¢æ®–ï¼Œå‡å°‘å®éªŒæ€§ç»“è‚ ç‚çš„å‘ç”Ÿï¼Œä¿æŠ¤å°è‚ å…å—å…ç–«ååº”çš„å½±å“ [<xref ref-type="bibr" rid="hanspub.39999-ref25">25</xref>]ã€‚IL-35çš„ä¸€ä¸ªäºšå•ä½Ebi3åœ¨EBVè½¬åŒ–çš„Bæ·‹å·´ç»†èƒå’Œç»„ç»‡ä¸­å¹¿æ³›è¡¨è¾¾ï¼Œå¦‚æ‰æ¡ƒä½“å’Œè„¾è„ [<xref ref-type="bibr" rid="hanspub.39999-ref26">26</xref>]ã€‚Ebi3å¯è´Ÿæ€§è°ƒèŠ‚IL-17ï¼ŒIL-22å’ŒTh17è½¬å½•å› å­ROR Tï¼Œå‘æŒ¥æŠ—ç‚ä¿æŠ¤æ€§å…ç–« [<xref ref-type="bibr" rid="hanspub.39999-ref27">27</xref>]ã€‚IL-12äºšå•ä½p35å¯å¯¼è‡´å°é¼ ç–±ç–¹åŸºè´¨æ€§è§’è†œç‚(HSK)çš„è¿›å±•ï¼Œä¸IL-12p40æ— å…³ [<xref ref-type="bibr" rid="hanspub.39999-ref28">28</xref>]ã€‚IL-35çš„ä¸¤ä¸ªäºšå•ä½ç¡®å®å…·æœ‰è‡ªèº«è°ƒèŠ‚å…ç–«å’Œç‚ç—‡è¿‡ç¨‹çš„èƒ½åŠ›ã€‚å½“å®ƒä»¬ç»“åˆåœ¨ä¸€èµ·å½¢æˆå¼‚äºŒèšä½“æ—¶ï¼Œp35äºšåŸºå¯èƒ½èµ·é…ä½“çš„ä½œç”¨ï¼Œè€Œå¦ä¸€ä¸ªäºšåŸºEBI3å¯èƒ½ä¸»è¦å‘æŒ¥å…¶å…ç–«åŠŸèƒ½ [<xref ref-type="bibr" rid="hanspub.39999-ref29">29</xref>]ã€‚åˆ°ç›®å‰ä¸ºæ­¢ï¼ŒIL-35çš„ä¿¡å·è½¬å¯¼é€”å¾„å°šä¸æ¸…æ¥šã€‚åŒæ—¶ï¼Œç ”ç©¶è¯å®IL-35é€šè¿‡ç‹¬ç‰¹çš„å—ä½“é“¾å¼‚æºäºŒèšä½“IL-12 R2å’Œgp130æˆ–æ¯æ¡é“¾çš„åŒæºäºŒèšä½“è¿›è¡Œä¿¡å·ä¼ é€’ [<xref ref-type="bibr" rid="hanspub.39999-ref30">30</xref>]ã€‚é€šè¿‡IL-35å—ä½“çš„ä¿¡å·ä¼ å¯¼éœ€è¦è½¬å½•å› å­STAT1å’ŒSTAT4ï¼ŒSTAT1å’ŒSTAT4å½¢æˆç‹¬ç‰¹çš„å¼‚æºäºŒèšä½“ï¼Œç»“åˆåˆ°ç¼–ç IL-12äºšåŸºp35å’ŒEBI3çš„åŸºå› å¯åŠ¨å­ä¸­çš„ä¸åŒä½ç‚¹ã€‚IL-35å¯ç›´æ¥æŠ‘åˆ¶Teffç»†èƒå¢æ®–ï¼Œå°†åŸå§‹Tç»†èƒè½¬åŒ–ä¸ºäº§ç”ŸIL-35çš„iTr35ç»†èƒï¼ŒæŠ‘åˆ¶Th17ç»†èƒçš„å‘è‚²ï¼Œå¹¶ä»‹å¯¼IL-10çš„äº§ç”Ÿã€‚åŒæ ·ï¼ŒIL-37æ˜¯ç‚ç—‡ã€è‡ªèº«å…ç–«å’Œå…¶ä»–å…ç–«å­¦ç–¾ç—…çš„ç»†èƒå› å­ã€‚IL-37è›‹ç™½åœ¨ç±»é£æ¹¿æ€§å…³èŠ‚ç‚æ‚£è€…çš„æ»‘è†œç»†èƒä¸­é«˜è¡¨è¾¾ï¼Œä½†åœ¨å¥åº·äººæ»‘è†œç»†èƒä¸­è¡¨è¾¾ä½æ°´å¹³ [<xref ref-type="bibr" rid="hanspub.39999-ref31">31</xref>]ã€‚é“¶å±‘ç—…æ‚£è€…çš„çš®æŸå’Œå…‹ç½—æ©ç—…çš®æŸçš„å·¨å™¬ç»†èƒä¸­IL-37çš„è¡¨è¾¾ä¹Ÿæ˜¾è‘—å¢åŠ  [<xref ref-type="bibr" rid="hanspub.39999-ref27">27</xref>]ã€‚IL-37æ˜¯ä½œä¸ºå‰è›‹ç™½åˆæˆçš„ï¼Œåœ¨åˆºæ¿€åï¼Œå®ƒè¢«åŠ å·¥æˆæˆç†Ÿå½¢å¼ [<xref ref-type="bibr" rid="hanspub.39999-ref32">32</xref>]ã€‚è„‚å¤šç³–(LPS)ä¸å…¶ä»–ç‚ç—‡åˆºæ¿€ç‰©å’Œç»†èƒå› å­ä¸€èµ·æ¿€æ´»caspase-1ï¼Œè¢«è®¤ä¸ºæ˜¯è´Ÿè´£IL-1å®¶æ—å‰ä½“æˆç†Ÿçš„ä¸»è¦è£‚è§£é…¶ã€‚IL-37å…·æœ‰æŠ—èŒï¼ŒæŠ—ç—…æ¯’ï¼Œä¸­å’Œå†…æ¯’ç´ ï¼ŒæŠ—è‚¿ç˜¤ï¼Œå…ç–«è°ƒèŠ‚ç­‰å¹¿è°±åŠŸèƒ½ï¼Œå¯¹å¾®ç”Ÿç‰©å…·æœ‰æ™®éçš„æ€ç­ä½œç”¨ã€‚å…¶ä½œç”¨æœºåˆ¶ä¸»è¦æ˜¯é€šè¿‡æ”¹å˜ç»†èŒç»†èƒçš„é€šé€æ€§ã€‚å®ƒè¿˜å…·æœ‰æé«˜IL-8ç­‰å‡ ç§ç»†èƒå› å­çš„äº§ç”Ÿä»¥æ‰©å¤§è·å¾—æ€§å…ç–«åŠŸèƒ½çš„èƒ½åŠ› [<xref ref-type="bibr" rid="hanspub.39999-ref33">33</xref>]ã€‚å¯¹å°é¼ æ¨¡å‹çš„ç ”ç©¶å·²ç»å¾—å‡ºIL-37ä¸‹è°ƒç‚ç—‡çš„ç»“æœã€‚TLRã€è‚¿ç˜¤åæ­»å› å­(TNF)ç­‰ç»†èƒå› å­å¯è¯±å¯¼ç‚æ€§ç»†èƒå› å­çš„äº§ç”Ÿã€‚è¯ºå¾·ç­‰äººæŠ¥é“IL-37å‡å¼±ä¸Šè¿°è¿‡ç¨‹ï¼Œä»è€Œå‘æŒ¥æŠ—ç‚ä½œç”¨ [<xref ref-type="bibr" rid="hanspub.39999-ref31">31</xref>]ã€‚</p><p>æœ¬ç ”ç©¶å­˜åœ¨æ½œåœ¨çš„å±€é™æ€§ã€‚ç¬¬ä¸€ï¼Œæ ·æœ¬é‡ç›¸å¯¹è¾ƒå°ã€‚å°½ç®¡æœ‰è¿™æ ·çš„å‘ç°ï¼Œæ˜¾ç„¶éœ€è¦è¿›è¡Œå¤§è§„æ¨¡çš„å‰ç»æ€§ç ”ç©¶æ¥ç¡®å®šOSASåŠå…¶äºšç»„çš„IL-35ã€IL-37æ°´å¹³ã€‚å…¶æ¬¡ï¼Œæˆ‘ä»¬çš„ç ”ç©¶ä¸åŒ…å«CPAPæ²»ç–—åçš„å—è¯•è€…çš„éšè®¿è®°å½•ï¼Œåº”è¿›ä¸€æ­¥ç ”ç©¶IL-35å’ŒIL-37çš„ä½œç”¨æœºåˆ¶ï¼Œä»¥ä½¿å…¶åœ¨ä»Šåçš„ç ”ç©¶ä¸­å¾—åˆ°åº”ç”¨ã€‚</p></sec><sec id="s9"><title>5. ç»“è®º</title><p>ç»¼ä¸Šæ‰€è¿°ï¼Œå¯¹OSASæ‚£è€…ç‚ç—‡å’Œæ°§åŒ–åº”æ¿€çŠ¶æ€çš„è¿›ä¸€æ­¥ç ”ç©¶å°†æœ‰åŠ©äºå…¨é¢ã€æ·±å…¥åœ°è®¤è¯†OSASçš„å‘ç—…æœºåˆ¶ã€‚å°½ç®¡å„ç§ç ”ç©¶è¯å®ç‚ç—‡å› å­åŠä»£è°¢æŒ‡æ ‡æœ‰åŠ©äºOSASçš„ä¸¥é‡æ€§çš„é¢„æµ‹ï¼Œä½†æ›´å‡†ç¡®ã€æ›´ç†æƒ³çš„æŒ‡æ ‡æœ‰å¾…äºè¿›ä¸€æ­¥å‘ç°åŠä¸´åºŠéªŒè¯åº”ç”¨ã€‚ç‚ç—‡å› å­å’Œé˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœä½é€šæ°”ç»¼åˆå¾ä¸¥é‡ç¨‹åº¦çš„ç›¸å…³æ€§ï¼Œæå‡ºäº†å¯èƒ½çš„æ–°çš„æ£€éªŒæŒ‡æ ‡ï¼Œä¸ºæ·±å…¥æ¢è®¨OSAHSçš„å‘ç—…æœºåˆ¶ã€ä¸´åºŠè¯„ä¼°ã€é¢„ååŠç–—æ•ˆè¯„ä¼°æä¾›ä¸€å®šçš„å‚è€ƒä»·å€¼ã€‚</p></sec><sec id="s10"><title>æ–‡ç« å¼•ç”¨</title><p>ææ ‹æ‰,ç¨‹æ¶µè“‰,é­æ°¸è‰. å„¿ç«¥é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœç»¼åˆå¾æ‚£å„¿è¡€æ¸…IL-35å’ŒIL-37æ°´å¹³çš„ç ”ç©¶Serum IL-35 and IL-37 Levels in Pediatrics with Obstructive Sleep Apnea Syndrome[J]. ä¸´åºŠåŒ»å­¦è¿›å±•, 2021, 11(01): 268-274. https://doi.org/10.12677/ACM.2021.111039</p></sec><sec id="s11"><title>å‚è€ƒæ–‡çŒ®</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39999-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Taioufis, C., Thornopoulos, K., Dimitriadis, K., Anastasia, A., Dimitris, T., Christodoulos, S., et al. (2007) The Incremental Effect of Obstructive Sleep Apnoea Syndrome on Arterial Stiffness in Newly Diagnosed Essential Hypertensive Subjects. Journal of Hypertension, 26, 141-146. &lt;br&gt;https://doi.org/10.1097/HJH.0b013e32801092c1</mixed-citation></ref><ref id="hanspub.39999-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bhushan, B., Guleria, R., Misra, A., Pandey, R.M., Luthra, K., Vikram, N.K., et al. (2009) Obstructive Sleep Apnoea Correlates with C-Reactive Protein in Obese Asian Indians. Nutrition, Metabolism and Cardiovascular Diseases, 19, 184-189. &lt;br&gt;https://doi.org/10.1016/j.numecd.2008.06.008</mixed-citation></ref><ref id="hanspub.39999-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Collison, L.W., Workman, C.J., Kuo, T.T., Boyd, K., Wang, Y., Vignali, K.M., et al. (2007) The Inhibitory Cytokine IL-35 Contributes to Regulatory T-Cell Function. Nature, 450, 566-569. &lt;br&gt;https://doi.org/10.1038/nature06306</mixed-citation></ref><ref id="hanspub.39999-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chaturvedi, V., Collison, L.W., Guy, C.S., Workman, C.J. and Vignali, D.A.A. (2011) Cutting Edge: Human Regulatory T Cells Require IL-35 to Mediate Suppression and Infectious Tolerance. Journal of Immunology, 186, 6661-6666.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.1100315</mixed-citation></ref><ref id="hanspub.39999-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Mai, J., Virtue, A., Yin, Y., Gong, R., Sha, X., et al. (2012) IL-35 Is a Novel Responsive Anti-Inflammatory Cytokineâ€”A New System of Categorizing Anti-Inflammatory Cytokines. PLoS ONE, 7, e33628. 
&lt;br&gt;https://doi.org/10.1371/journal.pone.0033628</mixed-citation></ref><ref id="hanspub.39999-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lee, Y.K. and Mazmanian, S.K. (2010) Has the Microbiota Played a Critical Role in the Evolution of the Adaptive Immune System? Science, 330, 1768-1773. &lt;br&gt;https://doi.org/10.1126/science.1195568</mixed-citation></ref><ref id="hanspub.39999-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chen, P. and Fang, S. (2004) The Expression of Human Antimicrobial Peptide LL-37 in the Human Nasal Mucosa. The American Journal of Rhinology, 18, 381-385. &lt;br&gt;https://doi.org/10.1177/194589240401800608</mixed-citation></ref><ref id="hanspub.39999-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Guilleminault, C., Tilkian, A. and Dement, W.C. (1976) The Sleep Apnea Syndromes. Annual Review of Medicine, 27, 465-484. &lt;br&gt;https://doi.org/10.1146/annurev.me.27.020176.002341</mixed-citation></ref><ref id="hanspub.39999-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Marcus, C.L., Brooks, L.J., Draper, K.A., Gozal, D., Halbower, A.C., Jones, J., et al. (2012) Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome, Pediatrics, 130, 576-584.  
&lt;br&gt;https://doi.org/10.1542/peds.2012-1671</mixed-citation></ref><ref id="hanspub.39999-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">ä¸­ååŒ»å­¦ä¼šå‘¼å¸ç—…å­¦åˆ†ä¼šç¡çœ å‘¼å¸éšœç¢å­¦ç»„. é˜»å¡æ€§ç¡çœ å‘¼å¸æš‚åœä½é€šæ°”åˆå¾è¯Šæ²»æŒ‡å—(2011å¹´ä¿®è®¢ç‰ˆ)[J].ä¸­åç»“æ ¸å’Œå‘¼å¸æ‚å¿—, 2012, 35(1): 9-12.</mixed-citation></ref><ref id="hanspub.39999-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">De Luca Canto, G., Pacheco-Pereira, C., Aydinoz, S., Major, P.W., Flores Mir, C. and Gozal, D. (2014) Biomarkers Associated with Obstructive Sleep Apnea: A Scoping Review. Sleep Medicine Reviews, 23, 28-45. 
&lt;br&gt;https://doi.org/10.1016/j.smrv.2014.11.004</mixed-citation></ref><ref id="hanspub.39999-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Katz, E.S. and Dâ€™Ambrosio, C.M. (2010) Pediatric Obstructive Sleep Apnea Syndrome. Clinics in Chest Medicine, 31, 221-234. &lt;br&gt;https://doi.org/10.1016/j.ccm.2010.02.002</mixed-citation></ref><ref id="hanspub.39999-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Farber, J.M. (2002) Clinical Practice Guideline: Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome. Pediatrics, 110, 1255-1257. &lt;br&gt;https://doi.org/10.1542/peds.110.6.1255-a</mixed-citation></ref><ref id="hanspub.39999-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ryan, S., Taylor, C.T. and McNicholas, W.T. (2009) Systemic Inflammation: A Key Factor in the Pathogenesis of Cardiovascular Complications in Obstructive Sleep Apnoea Syndrome. Thorax, 64, 631-636.</mixed-citation></ref><ref id="hanspub.39999-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Minoguchi, K., Tazaki, T., Yokoe, T., Minoguchi, H., Watanabe, Y., Yamamoto, M., et al. (2004) Elevated Production of Tumor Necrosis Factor-Alpha by Monocytes in Patients with Obstructive Sleep Apnea Syndrome. Chest, 126, 1473-1479. &lt;br&gt;https://doi.org/10.1378/chest.126.5.1473</mixed-citation></ref><ref id="hanspub.39999-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lui, M.M., Lam, J.C., Mak, H.K., Xu, A., Ooi, C., Lam, D.C., et al. (2009) C-Reactive Protein Is Associated with Obstructive Sleep Apnea Independent of Visceral Obesity. Chest, 135, 950-956. &lt;br&gt;https://doi.org/10.1378/chest.08-1798</mixed-citation></ref><ref id="hanspub.39999-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Mehra, R., Storfer-Isser, A., Kirchner, H.L., Johnson, N., Jenny, N., Tracy, R.P., et al. (2006) Soluble Interleukin 6 Receptor: A Novel Marker of Moderate to Severe Sleep-Related Breathing Disorder. Archives of Internal Medicine, 166, 1725-1731. &lt;br&gt;https://doi.org/10.1001/archinte.166.16.1725</mixed-citation></ref><ref id="hanspub.39999-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nural, S., Gunay, E., Halici, B., Celik, S. and Unlu, M. (2013) Inï¬‚ammatory Processes and Effects of Continuous Positive Airway Pressure (CPAP) in Overlap Syndrome. Inï¬‚ammation, 36, 66-74.  
&lt;br&gt;https://doi.org/10.1007/s10753-012-9520-z</mixed-citation></ref><ref id="hanspub.39999-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Svensson, M., Venge, P., Janson, C. and Lindberg, E. (2012) Relationship between Sleep-Disordered Breathing and Markers of Systemic Inï¬‚ammation in Women from the General Population. Journal of Sleep Research, 21, 147-154.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2869.2011.00946.x</mixed-citation></ref><ref id="hanspub.39999-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Yokoe, T., Minoguchi, K., Matsuo, H., Oda, N., Minoguchi, H., Yoshino, G., et al. (2003) Elevated Levels of C-Reactive Protein Andinterleukin-6 in Patients with Obstructive Sleep Apnea Syndrome Are Decreased by Nasal Continuous Positive Airway Pressure. Circulation, 107, 1129-1134.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.0000052627.99976.18</mixed-citation></ref><ref id="hanspub.39999-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Vgontzas, A.N., Papanicolaou, D.A., Bixler, E.O., Kales, A., Tyson, K. and Chrousos, G.P. (1997) Elevation of Plasma Cytokines in Disorders of Excessive Daytime Sleepiness: Role of Sleep Disturbance and Obesity. The Journal of Clinical Endocrinology and Metabolism, 82, 1313-1316. &lt;br&gt;https://doi.org/10.1210/jcem.82.5.3950</mixed-citation></ref><ref id="hanspub.39999-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zandian, M., Mott, K.R., Allen, S.J., Dumitrascu, O., Kuo, J.Z. and Ghiasi, H. (2011) Use of Cytokine Immunotherapy to Block CNS Demyelination Induced by a Recombinant HSV-1 Expressing IL-2. Gene Therapy, 18, 734-742. 
&lt;br&gt;https://doi.org/10.1038/gt.2011.32</mixed-citation></ref><ref id="hanspub.39999-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kochetkova, I., Golden, S., Holderness, K., Callis, G. and Pascual, D.W. (2010) IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10. Journal of Immunology, 184, 7144-7153. &lt;br&gt;https://doi.org/10.4049/jimmunol.0902739</mixed-citation></ref><ref id="hanspub.39999-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Whitehead, G.S., Wilson, R.H., Nakano, K., Burch, L.H., Nakano, H. and Cook, D.N. (2012) IL-35 Production by Inducible Costimulator (ICOS)-Positive Regulatory T Cells Reverses Established IL-17-Dependent Allergic Airways Disease. Journal of Allergy and Clinical Immunology, 129, 207-215.E5. &lt;br&gt;https://doi.org/10.1016/j.jaci.2011.08.009</mixed-citation></ref><ref id="hanspub.39999-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wirtz, S., Billmeier, U., McHedlidze, T., Blumberg, R.S. and Neurath, M.F. (2011) Interleukin-35 Mediates Mucosal Immune Responses That Protect against T-Cell-Dependent Colitis. Gastroenterology, 141, 1875-1886. 
&lt;br&gt;https://doi.org/10.1053/j.gastro.2011.07.040</mixed-citation></ref><ref id="hanspub.39999-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Devergne, O., Birkenbach, M. and Kieff, E. (1997) Epstein-Barr Virus-Induced Gene 3 and the p35 Subunit of Interleukin 12 form a Novel Heterodimeric Hematopoietin. Proceedings of the National Academy of Sciences of the United States of America, 94, 12041-12046. &lt;br&gt;https://doi.org/10.1073/pnas.94.22.12041</mixed-citation></ref><ref id="hanspub.39999-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yang, J., Yang, M., Htut, T.M., Ouyang, X., Hanidu, A., Li, X., et al. (2008) Epstein-Barr Virus-Induced Gene 3 Negatively Regulates IL-17, IL-22 and RORğ›¾t. European Journal of Immunology, 38, 1204-1214. 
&lt;br&gt;https://doi.org/10.1002/eji.200838145</mixed-citation></ref><ref id="hanspub.39999-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Frank, G.M., Divito, S.J., Maker, D.M., Xu, M. and Hendricks, R.L. (2010) A Novel P40-Independent Function of IL-12P35 Is Required for Progression and Maintenance of Herpes Stromal Keratitis. Investigative Ophthalmology and Visual Science, 51, 3591-3598. &lt;br&gt;https://doi.org/10.1167/iovs.09-4368</mixed-citation></ref><ref id="hanspub.39999-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ye, S., Wu, J., Zhou, L., Lv, Z., Xie, H. and Zheng, S. (2013) Interleukin-35: The Future of Hyperimmune-Related Diseases? Journal of Interferon and Cytokine Research, 33, 285-291. &lt;br&gt;https://doi.org/10.1089/jir.2012.0086</mixed-citation></ref><ref id="hanspub.39999-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Collison, L.W., Delgoffe, G.M., Guy, C.S., Vignali, K.M., Chaturvedi, V., Fairweather, D.L., et al. (2012) The Composition and Signaling of the IL-35 Receptor Are Unconventional. Nature Immunology, 13, 290-299.  
&lt;br&gt;https://doi.org/10.1038/ni.2227</mixed-citation></ref><ref id="hanspub.39999-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Nold, M.F., Nold-Petry, C.A., Zepp, J.A., Palmer, B.E., Bufler, P. and Dinarello, C.A. (2010) IL-37 Is a Fundamental Inhibitor of Innate Immunity. Nature Immunology, 11, 1014-1022. &lt;br&gt;https://doi.org/10.1038/ni.1944</mixed-citation></ref><ref id="hanspub.39999-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Boraschi, D., Lucchesi, D., Hainzl, S., Leitner, M., Maier, E., Mangelberger, D., et al. (2011) IL-37: A New Anti-Inflammatory Cytokine of the IL-1 Family. European Cytokine Network, 22, 127-147.  
&lt;br&gt;https://www.jle.com/10.1684/ecn.2011.0288</mixed-citation></ref><ref id="hanspub.39999-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">de Smet, K. and Contreras, R. (2005) Human Antimicrobial Peptides: Defensins, Cathelicidins and Histatins. Biotechnology Letters, 27, 1337-1347. &lt;br&gt;https://doi.org/10.1007/s10529-005-0936-5</mixed-citation></ref></ref-list></back></article>